Integer Holdings Corporation, a leading medical device contract development and manufacturing organization, reported a total revenue of $1.85 billion for the fiscal year ending December 31, 2025, marking an 8% increase from $1.72 billion in 2024. The growth was primarily driven by a 16.6% increase in the Cardio & Vascular segment, which generated $1.11 billion in sales, and a modest 1.2% rise in the Cardiac Rhythm Management & Neuromodulation segment, which brought in $668.8 million. However, sales from Other Markets declined by 26.9% to $77.8 million, largely due to the company's planned exit from the Portable Medical market.
Despite the revenue growth, Integer's net income from continuing operations fell to $102.8 million, or $2.89 per diluted share, down from $121.1 million, or $3.40 per diluted share, in the previous year. This decline in profitability was attributed to increased operating expenses, which rose by 11.3% to $279.1 million, driven by higher selling, general, and administrative costs, as well as restructuring charges. Additionally, the company incurred a significant $53.2 million in other losses, primarily due to a debt conversion inducement expense related to the exchange of its 2028 Convertible Notes.
In terms of strategic developments, Integer executed several acquisitions in 2025, including Precision Coating LLC, VSi Parylene, and Biocoat, which collectively enhanced its capabilities in high-value surface coating technologies. These acquisitions are expected to bolster Integer's position in the Cardio & Vascular and Neuromodulation markets. The company also reported a firm backlog of approximately $675 million as of December 31, 2025, indicating strong future demand.
Operationally, Integer employed around 11,000 associates as of the end of 2025, with a significant portion of its workforce based in the U.S. (43%) and Mexico (25%). The company continues to focus on enhancing its operational efficiency through initiatives like the Integer Operating System and Integer Production System, aimed at optimizing processes and improving overall performance. Looking ahead, Integer anticipates challenges in 2026 due to lower sales from new products that have not achieved expected market adoption, but remains optimistic about its long-term growth prospects driven by its strategic acquisitions and market position.
About Integer Holdings Corp
Integer Holdings Corporation is a leading medical device contract manufacturer specializing in cardiac rhythm management, neuromodulation, and vascular markets. It develops and produces innovative components, sub-assemblies, and finished devices for OEMs worldwide. The company emphasizes high-quality, regulatory-compliant solutions, leveraging advanced technologies and strategic acquisitions to serve large healthcare providers and medical device companies in growth-oriented segments.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.